Previous Studies

2025

• A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 to Placebo MDI and Open-Label Ventolin® Evohaler in Adult Participants with Asthma (MITCHELL)

• A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy & Safety of Tozorakimab in Adult Participants with Uncontrolled Asthma on Med-to-High Dose Inhaled Corticosteroids (UMBRIEL)

2024

• A Randomized, Open Label, Active-Controlled, Parallel-Group, Multiple-Dose, Multiple-Site, Patient Use Study to Obtain Partially Used Test Fluticasone Propionate Inhalation Aerosol, 110 mg (Teva) Devices and Reference FLOVENT HFA (fluticasone propionate inhalation aerosol), 110 mg (GlaxoSmithKline) Devices, After Repeated Use in Patients with Asthma

• A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 24 weeks in participants with eosinophilic asthma (EXHALE-4)

• A Randomized, Placebo-controlled, Double-blind, Multicenter, 12-Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma

2023

• A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24μg total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800μg total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid.

2022

• Randomized, Double-Blind, Parallel Group, Multicenter 24 Week Study to Assess the Efficacy and Safety of Budesonide and FormoterolFumarate Metetered Dose Inhaler Relative to Budesonide Metered Dose Inhaler and Open-Label Symbicort® Turbuhaler® in Participants with Inadequately Controlled Asthma

• A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product (Cipla Ltd.) in comparison with the Reference Product, Symbicort® (Budesonide/Formoterol Fumarate Dihydrate, 80/4.5 μg per Actuation) Inhalation Aerosol (AstraZeneca, USA), in Adult Asthma Patients.

• Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared to BGF delivered by MDI HFA in Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

2021

• A first in human, double-blind, placebo-controlled, multicentre Phase I/II study to evaluate the safety, tolerability and immune modulatory effects of MRx-4DP0004 (a lyophilised formulation of Bifidobacterium breve proprietary strain of 4D Pharma Research) in participants taking long-term control medication for their asthma

• A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV-53275 Administered Subcutaneously in Adult Patients with Persistent Eosinophilic Asthma

• A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® Pressurized MDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS)

• Pilot Clinical Pharmacodynamic (PD) Bioequivalence (BE) Study of Ipratropium Bromide HFA MDI (A007) in Treatment for Chronic Obstructive Pulmunary Disease (COPD)

2020

• A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Biomarker Study of the Effects of Dexpramipexole on Eosinophils in Subjects with Eosinophilic Asthma

• A 12-week, Randomized, Double-blind, Placebo-controlled, Multicenter,Parallel Group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT008 and PT007 Administered QID in Adults and Children 4 Years of Age or Older with Asthma

2019

• A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Parallel Arm, Multi-Centre Study to Assess Efficacy and Safety of Multiple Dose Levels of AZD7594 DPI Given Once Daily for twelve weeks, compared to placebo, in Asthmatics symptomatic on low dose ICS

• A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100mcg/50mcg (Supplied by Teva Pharmaceuticals Ireland) to ADVAIR DISKUS® 100/50mcg

• A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to compare the Therapeutic Eqivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110mcg, to Flovent® HFA 110mcg, in Adult Subjects with Asthma.

• A Cross-Sectional and Longitudinal Observational Primary Data Collection Study to Assess the Validity of the US Asthma Impairment and Risk Questionnaire (AIRQ TM) as a tool that identifies Patients with Asthma at Risk for Adverse Outcomes from Uncontrolled Asthma

• Pharmacodynamic (PD) Bronchodilatation Bioequivalence (BE) Study of Albuterol Sulfate HFA MDI 90 mcg/inhalation in Asthma Patients (3) Subtitle: A Randomized, Single-Dose, Double-Blinded, Double-Dummy,Placebo- Controlled, Five-Treatment, Crossover PD Study

2018

• A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent Asthma

• A randomized, double-blind, placebo-controlled, parallel-group, 12-week Proof-of-Concept (PoC) study to assess the efficacy, safety, and tolerability of SAR440340, and the coadministration of SAR440340 and dupilumab in patients with moderate-to-severe asthma who are not well controlled on inhaled corticosteroid (ICS) plus long-acting β2 adrenergic agonist (LABA) therapy

• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety,Tolerability, Pharmacokinetics, and Immunogenicity of TEV-48574 Following Subcutaneous Single Doses in Healthy Subjects and Subcutaneous Multiple Doses in Asthma Patients

• A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 μg and Salmeterol Xinafoate 50 μg Inhalation Powder Compared with Advair Diskus® 100/50 in Subjects with Asthma

• A multicenter, randomized, parallel-group, placebo controlled, 4-week clinical endpoint bioequivalence study comparing fluticasone propionate/salmeterol 100/50 μg inhalation powder (Cipla Ltd., India) with Advair® Diskus 100/50 μg (GlaxoSmithKline, USA) in asthma patients

2017

• A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter Clinical Study to Assess the Efficacy and Safety of Twice Daily Administration of Fluticasone Propionate and Salmeterol Inhalation Powder 100/50 mcg Compared to Administration of ADVAIR DISKUS® 100/50 mcg Twice Daily and Placebo in Patients 12 Years of Age and Older with Reversible Persistent Asthma including a 3-Week Open-Label Extension to Assess Inhaler Robustness

• An 8 week, randomized, double blind, placebo and active-controlled, parallel group, dose ranging study to evaluate the efficacy and safety of 3 doses of CHF 718 (Beclomethasone dipropionate) in asthmatic subjects

• A 12-week, multicenter, randomized, double-blind, placebocontrolled study to assess the efficacy and safety of QAW039 when added to standard-of-care asthma therapy in patients with uncontrolled asthma

• A multi-center randomized 52-week treatment, double-blind, tripledummy, parallel-group study, to assess the efficacy and safety of QMF149 compared with mometasone furoate in patients with asthma

2016

• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Delivered via Breath Actuated Inhaler (BAI) at 320 or 640 mcg/day in Adolescent and Adult Patients 12 Years of Age and Older with Persistent Asthma

• A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, 5-Treatment, Randomized, Crossover Study to Demonstrate the Pharmacodynamic Bioequivalence of Test and Reference Metered Dose Inhalers containing Albuterol Sulfate using Bronchoprovocation in Adult Patients with Stable Mild Asthma

• A phase III double blind, double blind, 6-arm parallel group, comparing the efficacy, safety and tolerability of the fixed dose of combination FF/UMEC/VI with the fixed dose dual combination of FF/VI, administered once-daily via a DPI in subjects with inadaquately controlled asthma.(Fluticasone Furoate/Vilanterol/Umeclidinium)

• Pilot Clinical Endpoint (CE) Bioequivalence (BE) Study of Beclomethasone Dipropionate HFA MDI (Q001) 40 mcg/inhalation Versus QVAR Inhalation Aerosol 40 mcg/inhalation in Asthma Patients

• A Randomized, Single-Blind, Parallel-Group, Placebo-Controlled, Multidose Study Comparing the Therapeutic Equivalence of a 3M Inhaler and a Symbicort® Reference Inhaler, Each Delivering Budesonide/Formoterol Fumarate (80 μg/4.5 μg) in Adult Subjects With Asthma

• A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter, Multinational Study to Compare the Therapeutic Equivalence of a Budesonide 80 mcg/Formoterol Fumarate Dihydrate 4.5 mcg Inhalation Aerosol (manufactured by Catalent for Watson Laboratories Inc.) to Symbicort®

2015

• Pilot Clinical Endpoint Bioequivalence (BE) Study of Fluticasone Propionate HFA MDI 44mch/inhalation (F007) Versus Flovent (44mcg/inhalation) in Asthma Patients (A Randomized, Double-blinded, Placebo and Active-controlled, Multiple-Dose, 4-arm, 12 week Parallel Study).

• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Delivered via Breath Actuated Inhaler (BAI) at 320 or 640 mcg/day in Adolescent and Adult Patients 12 Years of Age and Older with Persistent Asthma

• A Phase 2, Multicenter, Randomized, Double- blind, Placebo-controlled, Dose-ranging Study of Vapendavir in Moderate to Severe Asthmatic Adults with Symptomatic Human Rhinovirus Infection

2014

• A Phase III, Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in patients with uncontrolled asthma who are on oinhaled corticosteroids and a second controller medication.

• A Randomized, Double-Blind, Double-Dummy,Placebo-Controlled, Parallel-Group, 12 week Clinical Study to Assess the Efficacy and Safety of 320 or 640 Mcg/Day of Beclomethasone Dipropionate delivered via Breath-Actuated Inhaler (BAI) or Metered Dose Inhaler (MDI) in Adolescent and Adult Patients 12 years of age and older with Persistent Asthma.

• A Randomized, Double Blind, Double Dummy, Placebo Controlled, Parallel Group, 12 Week Clinical Study to Assess the Efficacy and Safety of 80 or 160 mcg/Day of Beclomethasone Dipropionate Delivered via Breath Actuated Inhaler (BAI) or Metered Dose Inhaler (MDI) in Pediatric Patients 5 Through 11 Years of Age with Persistent Asthma

• A Randomized, Double Blind, Placebo Controlled, Parallel Group, 12 Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate (80 and 160 mcg/day) Delivered via Breath Actuated Inhaler (BAI) in Adolescent and Adult Patients 12 Years of Age and Older with Persistent Asthma

• A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma

• A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients with Persistent Asthma Symptomatic Despite Low-dose Inhaled Corticosteroid Therapy

• A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients with Persistent Asthma Symptomatic Despite Inhaled Corticosteroid Therapy

• A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older with Persistent Asthma

• Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients with Asthma

• A Randomized, Double-Blind, Double Dummy, Parallel Group Study to Determine the Local Equivalence of Multiple Doses of MGR001 to Advair® Diskus® Administered via Oral Inhalation in Adult Asthma Patients

• A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared with Advair Diskus® 100/50 in Subjects with Asthma

2013

• A dose-ranging study of fluticasone furoate (FF) inhalation powder in children aged 5-11 years with asthma

• A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study of JNJ-38518168 in Symptomatic Adult Subjects with Uncontrolled, Persistent Asthma

• A Randomised, Double Blind, Placebo-Controlled, Multi-Centre, Parallel Group Study to Evaluate the Efficacy and Safety of ADC3680 Administered Once Daily as an Add-On Therapy to Inhaled Corticosteroids and when Co-Administered with Montelukast in Subjects with Inadequately-Controlled Asthma.

2012

• Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)

• Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma

• Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma

• Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

• Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma

• A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)

• A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241) (SPIRO)

• A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma (SITAR)

• Safety Study of Albuterol Spiromax® in Subjects With Asthma

• A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

• Clinical Study to Evaluate the Efficacy of VR506 Using a New Inhaler for the Treatment of Asthma

2011

• Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients

• Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients (Sweapea)

• BI 671800 in Asthmatic Patients on Inhaled Corticosteroids

• Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults with Uncontrolled Asthma

• A Study of the Bronchodilator Effect of Formoterol Fumarate Used in Combination With Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P06476 AM2)

• Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

• SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. (AUSTRI)

2010

• Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006

• A 6-week Study in Asthmatic Children Aged 6 to <12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo

• A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg (CHASE 3)

• Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids

• Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

• Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

• Efficacy and Safety of Different Doses of Indacaterol

• A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma

2009

• AMG 853 Phase 2 Study in Subjects With Inadequately Controlled Asthma

• A Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids (MOLLY)

• Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma

2008

• 4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma

• A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma

2007

• A Multi-center, Randomized, Placebo, Multi-Dose study to evaluate the efficacy of AMG 317 compared with placebo as measured by change in Asthma Control Questionnaire (ACQ) symptom scores from baseline to week 12

• Assessment of PFT, Safety, and PK of Zileuton Injection in Asthma Patients

• A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma.

• A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma

• Effectiveness and Safety Study for JNJ-18054478 in Asthma Patients.

• Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma

• Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04334AM1)

• Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)

• Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids

2006

• A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma

• A Study to Evaluate the Safety and Efficacy of HAE1 in Subjects With Moderate to Severe Allergic Asthma

• Control of Asthma Patients Symptomatic on Inhaled Corticosteroids

• Study of MAP0010 in Asthmatic Children and Adolescents"

• Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure

2005

• Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid

• Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.

• Safety Study of Zileuton Injection in Patients With Asthma

• Study Of Allergic Rhinitis In Patients Who Also Have Asthma

• Evaluation of Two Doses of QVAR Versus Placebo by Breath Operated and Metered Dose Inhalers in Moderate Asthmatic Adolescents and Adults on a Stable Regimen of Inhaled Corticosteroids

• Comparison of Two Bronchodilator Inhalers in Pediatric Asthmatics

• A 3-week Study Investigating Patient Use and Functionality of Formoterol in a Novel Inhalation Device in Patients With Asthma

• Study Evaluating Etanercept in Moderate to Severe Asthma

2004

• New Version Pulmicort Turbuhaler USA Children

• New Version Pulmicort Turbuhaler USA Adults

• Assess the Efficacy and Safety of Rhinocort Aqua

• Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic Children

• Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma

2003

• Efficacy of Symbicort pMDI Administered Once Daily in Children and Adolescents During 12 Weeks

• Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEM

• A study to compare the safety and effectiveness of 5 different ways of taking Pulmicort when given to asthma patients aged 12 years and above

• To compare the long term safety of Symbicort with budesonide alone, in adolescents and adults with asthma.

• To determine whether asthma control and reduced bronchial hyperresponsiveness could be achieved and maintained at a lower dose of inhaled corticosteroids with ADVAIR DISKUS twice-daily or FP twice-daily in adult and adolescent subjects with persistent asthma

2002

• To compare Symbicort with budesonide alone and formoterol alone in the treatment of asthma in children aged 6 to 11 years

• Compare Symbicort with budesonide alone and with formoterol alone in the treatment of asthma in adolescents and adults

• Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler

• A one year study comparing the safety and effectiveness of Pulmicort (0.5mg strength given once a day in the evening) with either 4 or 5mg strength SINGULAR (given once a day in the evening) in children with asthma aged 2 to 8.

• Investigate the efficacy and safety of fexofenadine 120mg BID compared to placebo in the treatment of subjects with mild to moderate persistent asthma

• Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma

• Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma

2001

• To demonstrate if once-daily dosing of ADVAIR 100/50 once-daily has superior efficacy and comparable safety compared with FP 100mcg once-daily in pediatric subjects 4 to 11 years of age with asthma.

• A Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma

2000

• A Safety and Efficacy Study of Two Dosage Levels of Pulmicort Respules (budesonideinhalation suspension, 0.5 or 1.0 mg/day) versus Placebo in Infants Between the Ages of Six and TwelveMonths with Mild to Moderate Asthma.

• A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88mcg BID, 220mcg BID, and 440mcg BID versus Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma who are Maintained on Inhaled Corticosteroid Therapy

• A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88mcg BID, 220mcg BID, and 440mcg BID versus Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma who are Maintained on Bronchodilator Therapy

• Double-blind, doubledummy, comparing 88 mcg BID, 44 mcg BID and Placebo delivered via MDI with CFC propellants

1999

• Albuterol Sulfate Delivered from the Autohaler tm Inhalation Device, and HFA-placebo in Patients with Asthma.

• A 12-Week Comparison of Daily Doses of 100 mcg and 200mcg of HFA-134a Beclomethasone Dipropionate in the Autohaler Device vs. Placebo in Pediatric Patients with Symptomatic Asthma

• A Randomized, Double-Blind, Active-Controlled, Parallel-Group 12-Week Trial Evaluating the Safety and Efficacy of the 50/100mcg Salmeterol/Fluticasone Propionate DISKUS Combination Product twice daily Compared with Salmeterol 50mcg via DISKUS twice daily and Fluticasone Propionate 100mcg via DISKUS twice daily in Adult and Adolescent Subjects with Asthma on Short-Acting Beta2-Agonist Therapy

• Addition to inhaled corticosteroids of long‐acting beta2‐agonists versus anti‐leukotrienes for chronic asthma

• A randomized, double‐blind, parallel group, comparative trial of salmeterol/fluticasone propionate combination product 50/100mcg twice daily diskus versus fluticasone propionate 250 mcg twice daily diskus in adolescents and adults with moderate to persistent asthma.

• A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial to Determine the Efficacy of Oral Zafirlukast (ACCOLATE) When Administered According to Current Labeling Instructions or Simplified Dosing Instructions in Subjects With Asthma Receiving Inhaledb2-agonist Alone or Inhaled b2-agonist in Combination With Inhaled Corticosteroids

• A randomized, double‐blind, parallel‐group trial of inhaled fluticasone propionate/GR106642X 220mcg BID and 440mcg BID in adolescent and adult subjects with asthma

1998

• A Multicenter, Randomized, Double-blind, Dose Escalation Trial to Compare the Effect of Oral Doses of Zafirlukast (ACCOLATE ) in Subjects with Mild to Moderate Asthma.

• A Multicenter, Double-blind Comparison of Zafirlukast (ACCOLATE) with Placebo in Pediatric Subjects with Mild-to-moderate Asthma.

1997

• A Randomized, Double‐Blind, Placebo‐Controlled Comparative Trial of Fluticasone Propionate 440mcg BID or 880mcg BID versus Placebo Administered via Metered‐Dose Inhaler in Propellant 11/12 or GR106642X in Adolescent and Adult Oral Corticosteroid Dependent Asthmatics

• A Randomized, Double-Blind, Double-Dummy, Parallel Group, Comparative Study of Inhaled Fluticasone Propionate 88mcg BID versus Zafirlukast 20mg BID in Asthmatic Subjects who are Currently Receiving Low Dose Inhaled Corticosteroids

• Placebo-Controlled Efficacy and Safety Study with Long-Term Safety Evaluation of Mometasone Furoate HFA-227 Metered Dose Inhaler in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Beta-Agonists

• Randomized, double-blind, placebo-controlled efficacy and safety trial in patients ages 12 to 83 years with severe asthma

• 12-week, randomized, active-and placebo-controlled, parallel group, double-blind, double dummy trial in 435 patients aged 12 to 81 years with moderately severe asthma.

1996

• A Randomized, Double-Blind, Parallel-Group Trial Evaluating Safety and Efficacy of Salmeterol 50mcg BID and Fluticasone Propionate 250mcg BID Individually and in Combination and Placebo in Subjects with Asthma.

• A randomised, double-blind clinical trial comparing the efficacy and safety of salmeterol xinafoate 42mcg b.i.d.* plus fluticasone propionate 88mcg b.i.d.* versus fluticasone propionate 220mcg b.i.d.* alone in subjects with asthma not well controlled on fluticasone propionate 88mcg b.i.d.*

2024

• A Randomised, Placebo-controlled, Double-blind, Multi-centre, 4-week, 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared with BGF Delivered by MDI HFA with COPD

2023

• Cascade Lung: Cancer Screening Assay using DELFI; A Clinical Validation Study in Lung

2022

• A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel˗Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva® HandiHaler®)

• Clinical Pharmacodynamic (PD) Bioequivalence (BE) Study of Ipratropium Bromide HFA MDI (A007) in Treatment for Chronic Obstructive Pulmonary Disease (COPD) A Randomized, Single-Dose, Double-Blinded, Double-Dummy, Placebo-Controlled, Three-Treatment, Crossover, PD Study

• A Randomized, Double-Blind, 12-Week (with an Extension to 52 Weeks in a subset of Participants,

• Phase I, Randomised, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of AZD8630 in Healthy Adult Subjects (Part A) and Adults with Asthma on Medium to High Dose Inhaled Corticosteroids and Long-acting Beta-agonists (Part B)

• Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared to BGF delivered by MDI HFA in Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

2021

• Pilot Clinical Pharmacodynamic (PD) Bioequivalence (BE) Study of Ipratropium Bromide HFA MDI (A007) in Treatment for Chronic Obstructive Pulmunary Disease (COPD)

2018

• A Phase IV, 12-week, randomised, double-blind, triple dummy study to compare single inhaler triple therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) with multiple inhaler therapy (budesonide/formoterol plus tiotropium) based on lung function and symptoms in participants with chronic obstructive pulmonary disease

2017

• A randomized, double-blind, placebo-controlled, incomplete unbalanced, crossover study to assess the efficacy and safety of three doses of formoterol fumarate in Pressair® compared with Perforomist® Inhalation Solution (20 and 40 μg open-label) in moderate to severe COPD patients with reversible airway disease.

• A Phase 3b, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Study to Compare Once Daily Nebulized Revefenacin with Spiriva Once Daily Delivered via the HandiHaler® on Lung Function in Subjects with Chronic Obstructive Pulmonary Disease and a Low Peak Inspiratory Flow Rate

• A 6 week, randomized, double blind, placebo and active-controlled, parallel group, dose ranging study to evaluate the efficacy and safety of 4 doses of CHF 5259 pMDI (glycopyrronium bromide) in subjects with COPD

2015

• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Trial of 12 Weeks of Treatment with Nebulized SUN-101 in Patients with COPD: GOLDEN-4 (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer)

• A multi-center, randomized, double-blind, double-dummy, active controlled, 2-period cross-over study to assess the efficacy, safety and tolerability of indacaterol maleate/glycopyrronium bromide compared to umeclidinium bromide/vilanterol in COPD patients with moderate to severe airflow limitation

• A Randomized, Double-Blind, Multi-Center, Parallel Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD

• A Phase 3, 12-week, Randomized, Double−Blind Placebo−Controlled Parallel-Group Study of Nebulized TD−4208 in Subjects with Chronic Obstructive Pulmonary Disease

2014

• A 28-Week, Multi-Center, Randomized, Double-Blind, Parallel-Group, Active-Controlled Safety Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® as an Active Control

• A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® pMDI 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in COPD Patients

• A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter, Long-Term Safety Study Trial of Treatment With Nebulized SUN-101 in Patients With COPD: GOLDEN-5 (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer)

2013

• A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease

• A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients

• A 12-week treatment, multi-center, randomized, double-blind, double-dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 compared to fluticasone/salmeterol in COPD patients with moderate to severe airflow limitation"

• A Randomized, Double-Blind (Test Products and Placebo), Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo

2012

• Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

2011

• Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

2010

• A 26-week Treatment Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled (Open Label) Study to Assess the Efficacy, Safety and Tolerability of QVA149 (110/50 μg q.d.) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

2007

• Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

2004

• A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients

• A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD

• Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease

• ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations.

2002

• Determining the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD

2001

• See if fluticasone 500mcg/salmeterol 50mcg can improve the survival of subjects with COPD and also assess the long term safety profile of this drug.

2000

• Ipratropium bromide versus long‐acting beta‐2 agonists for stable chronic obstructive pulmonary disease

2024

• A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/LY3650150 in Adult Participants with Perennial Allergic Rhinitis

2022

• A randomised, double-blind, placebo-controlled clinical trial to evalute the efficacy and safety of PQ Grass in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen exposure

2021

• A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy of Anti-Bet V1 Monoclonal Antibodies to Reduce Symptoms of SAR

• A Randomized, Double-Blind, Placebo-Controlled Study in Cat-Allergic Patients With Allergic Rhinitis Who Live With a Cat to Assess the Efficacy and Safety of Anti-Fel D1 Antibodies During Natural Cat Exposure in the Home

2018

• A Study To Evaluate The Efficacy Of Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy To Reduce Provoked Allergic Rhinitis Symptoms Using The Nasal Allergen Challenge Model

2015

• An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years after the Administration of Treatment

• A randomized, double-blind, placebo-controlled, multi-center study of the efficacy and safety of STG320 sublingual tablets of house dust mite (HDM) allergen extracts in

2014

• A Double-Blind, Randomized, Placebo-Controlled,Multi-Centre Field study to Assess the Efficacy and Safety of HDM-SPIRE in subjects with a history of House Dust Mite - Induced Rhinoconjunctivitis.

2013

• An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years after the Administration of Treatment

• MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis

2012

• Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)

• A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)

2011

• A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)

2010

• Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)

2000

• A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the effect of Long-term treatment with Rhinocort Aqua (Budesonide) Nasal Spray in Children with Perennial Allergic Rhinitis.

• A Randomized, Placebo-controlled, Parallel Group Multiple Dose Study of Rhinocort Aqua (budesonide) Nasal Spray on the Hypothalamic-Pituitary-Adrenal (HPA) Axis Function in Pediatric Patients with Allergic Rhinitis

1998

• Efficacy and Safety of Oglemilast in the Prevention of Allergen-induced Bronchospasm

2025

• A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participations with Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2)

2024

• Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Taplucainium Inhalation Powder (NOC-110) in Adults with Refractory or Unexplained Chronic Cough

2023

• A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough, Including Unexplained Chronic Cough (CALM-1)

2022

• A Randomized, Double-Blind, Placebo-Controlled, Two-Period crossover, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects with Chronic Cough

2020

• A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-selection study of S-600918 in patients with refractory chronic cough

2019

• A Phase 3b Randomized, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Adult Participants with Recent Onset Chronic Cough

2018

• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 IN Adult Participants with Chronic Cough

2017

• Randomized, double-blind, placebo controlled study of the efficacy, and tolerability of Serlopitant for the treatment of refractory chronic cough

2016

• A 12-Week Study to Assess the Efficacy and Safety of AF-219 in Subjects with Treatment Refractory Chronic Cough

2025

• A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Crossover Study to Evaluate the Efficacy and Safety of Lorundrostat in Participants with Moderate to Severe Obstructive Sleep Apnea and Hypertension

2024

• A Phase 3 Open-Label Continuation Protocol of a Fixed-Dose Combination of Aroxybutynin and Atomoxetine (AD109) in Obstructive Sleep Apnea

2023

• Phase 3 Randomized Double-Blind Placebo-Controlled 1 year Parallel-Arm Study to Compare a Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) to Placebo in Obstructive Sleep Apnea (LunAIRo Study)

Chronic Spontaneous Urticaria

2019

• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Crossover Study to Evaluate the Efficacy and Safety of LY3454738 in Adults With Chronic Spontaneous Urticaria Inadequately Controlled With H1-Antihistamines

2015

• A multicenter, randomized, double-blind, placebo and active-controlled phase 2b dose-finding study of QGE031 as add-on therapy to investigate the efficacy and safety in patients with Chronic Spontaneous Urticaria (CSU)

2011

• A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment

Pruritus

2019

• A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin

COVID-19/Flu, 2023

• Prospective Testing of Respiratory Samples at the Point-of-Care with Chembio DPP® Respiratory Antigen Panel

RSV, 2019

• A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of EDP-938 Administered Orally for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Ambulatory Adults

Flu, 2000

• A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10 mg Administered Once a Day for 28 Days in the Prevention of Symptomatic Influenza A and B Viral Infections in Community-Dwelling High-risk Subjects aged ≥12 years

Chronic Sinusitis, 2019

• A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 mcg of OPN-375 Twice a Day in Subjects with Chronic Sinusitis With or Without the Presence of Nasal Polyps

Non-allergic Rhinitis, 2005

• Study Of Adults And Adolescents With Vasomotor Rhinitis

Nasal Polyps

2018

• Open -label extension study of Omalizumab in patients with chronic rhinosinusitis with nasal polyps

2017

• A phase III, randomized, multicenter, double-blind, placebo-controlled clinical trial of Omalizumab in patients with chronic rhinosinusitis with nasal polyps

NanEntek FREND™ SHBG Test System, 2024

• Laboratory Use Method Comparison Studies and Reference Interval Determination for the NanEntek FREND tm SHBG Test System

CytoChip Cito CBC system, 2023

• The Cito CBC system from CytoChip (the Study Device) will be compared to Sysmex XN Hematology Analyzer (the Comparison Method) for the test performance of Complete Blood Count (CBC). Prospective samples collected from study subjects and archived blood Risk (ACHIEVE-4)

DPP® HIV-Syphilis Assay System, 2019

• DPP® HIV-Syphilis Assay System Reproducibility with HIV and Syphilis Samples

2023

• A Phase 3, Open-Label Study of Once Daily LY3502970 Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular

2023

• A prospective, Phase 3, randomized, multi-center, double-blind study of the efficacy, tolerability, and safety of oral sulopenem etzadroxil/probenecid versus oral amoxicillin/clavulanate for treatment of uncomplicated urinary tract infections (uUTI) in adult women

2024

• A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fasciitis (PFA)